PMID- 35849852
OWN - NLM
STAT- MEDLINE
DCOM- 20220803
LR  - 20220827
IS  - 1876-035X (Electronic)
IS  - 1876-0341 (Print)
IS  - 1876-0341 (Linking)
VI  - 15
IP  - 8
DP  - 2022 Aug
TI  - The clinical efficacy and safety of mesenchymal stromal cells for patients with 
      COVID-19: A systematic review and meta-analysis of randomized controlled trials.
PG  - 896-901
LID - S1876-0341(22)00179-4 [pii]
LID - 10.1016/j.jiph.2022.07.001 [doi]
AB  - OBJECTIVES: This meta-analysis of randomized controlled trials (RCTs) 
      investigated the usefulness of mesenchymal stromal cells (MSCs) to treat patients 
      with COVID-19. METHODS: PubMed, Embase, Ovid MEDLINE, the Cochrane Library, and 
      Clinicaltrials.gov were searched for RCTs published before November 7, 2021. Only 
      RCTs that compared the clinical efficacy and safety of MSCs with other 
      alternative treatments or placebos in the treatment of patients with COVID-19 
      were included. RESULTS: Six RCTs were included, in which the MSC and control 
      groups consisted of 158 and 135 patients, respectively. The patients who received 
      MSCs had a significantly lower 28-day mortality rate (7.6% vs 21.5%; OR, 0.18; 
      95% CI, 0.06-0.52; I(2) = 0%) and significantly higher clinical improvement rate 
      (OR, 6.05; 95% CI, 2.31-15.83; I(2) = 0%) than the controls. The patients who 
      received MSCs were associated with a similar risk of adverse events (AEs) and 
      serious AEs to the control group (AEs: OR, 33; 95% CI, 0.09-1.18; I(2) = 59%; 
      serious AEs: OR, 0.30; 95% CI, 0.02-4.41; I(2) = 53%). CONCLUSIONS: MSC treatment 
      may help to improve the clinical outcomes of patients with COVID-19. In addition, 
      MSC treatment appears to be a safe therapeutic option for patients with COVID-19.
CI  - Copyright (c) 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Chen, Ching-Yi
AU  - Chen CY
AD  - School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan; 
      Division of Pulmonary Medicine, Department of Internal Medicine, E-Da Hospital, 
      I-Shou University, Kaohsiung, Taiwan, College of Medicine, I-Shou University, 
      Kaohsiung, Taiwan.
FAU - Chen, Wang-Chun
AU  - Chen WC
AD  - Institute of Biotechnology and Chemical Engineering, I-Shou University, 
      Kaohsiung, Taiwan; Department of Pharmacy, E-Da Hospital, Kaohsiung, Taiwan.
FAU - Hsu, Chi-Kuei
AU  - Hsu CK
AD  - School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan; 
      Division of Pulmonary Medicine, Department of Internal Medicine, E-Da Hospital, 
      I-Shou University, Kaohsiung, Taiwan, College of Medicine, I-Shou University, 
      Kaohsiung, Taiwan; Department of Critical Care Medicine, E-Da Hospital, 
      Kaohsiung, Taiwan; School of Medicine, College of Medicine, I-Shou University, 
      Kaohsiung, Taiwan.
FAU - Chao, Chien-Ming
AU  - Chao CM
AD  - Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Taiwan.
FAU - Lai, Chih-Cheng
AU  - Lai CC
AD  - Division of Hospital Medicine, Department of Internal Medicine, Chi Mei Medical 
      Center, Tainan, Taiwan. Electronic address: dtmed141@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20220707
PL  - England
TA  - J Infect Public Health
JT  - Journal of infection and public health
JID - 101487384
SB  - IM
MH  - *COVID-19/therapy
MH  - Humans
MH  - *Mesenchymal Stem Cells
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
PMC - PMC9259515
OTO - NOTNLM
OT  - COVID-19
OT  - Mesenchymal stromal cell
OT  - Mortality
OT  - SARS-CoV-2
COIS- Competing interests This paper did not receive any funding. The authors have no 
      relevant affiliations or financial involvement with any organization or entity 
      with a financial interest in or financial conflict with the subject matter or 
      materials discussed in the manuscript. This includes employment, consultancies, 
      honoraria, stock ownership or options, expert testimony, grants, or patents 
      received or pending, or royalties.
EDAT- 2022/07/19 06:00
MHDA- 2022/08/04 06:00
PMCR- 2022/07/07
CRDT- 2022/07/18 18:12
PHST- 2022/04/29 00:00 [received]
PHST- 2022/06/22 00:00 [revised]
PHST- 2022/07/03 00:00 [accepted]
PHST- 2022/07/19 06:00 [pubmed]
PHST- 2022/08/04 06:00 [medline]
PHST- 2022/07/18 18:12 [entrez]
PHST- 2022/07/07 00:00 [pmc-release]
AID - S1876-0341(22)00179-4 [pii]
AID - 10.1016/j.jiph.2022.07.001 [doi]
PST - ppublish
SO  - J Infect Public Health. 2022 Aug;15(8):896-901. doi: 10.1016/j.jiph.2022.07.001. 
      Epub 2022 Jul 7.